[go: up one dir, main page]

WO2018009998A1 - Formulation mucosale antimicrobienne et utilisation d'une formulation mucosale antimicrobienne - Google Patents

Formulation mucosale antimicrobienne et utilisation d'une formulation mucosale antimicrobienne Download PDF

Info

Publication number
WO2018009998A1
WO2018009998A1 PCT/BR2017/050189 BR2017050189W WO2018009998A1 WO 2018009998 A1 WO2018009998 A1 WO 2018009998A1 BR 2017050189 W BR2017050189 W BR 2017050189W WO 2018009998 A1 WO2018009998 A1 WO 2018009998A1
Authority
WO
WIPO (PCT)
Prior art keywords
antimicrobial
mucosal
formulation according
mucosal formulation
silver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2017/050189
Other languages
English (en)
Portuguese (pt)
Inventor
Luiz Francisco Pianowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2018009998A1 publication Critical patent/WO2018009998A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • the present invention relates to a mucosal adherent antimicrobial mucosal formulation comprising silver particles, particularly silver micro or nanoparticles, for the prevention or treatment of mucosal disorders. It further relates to the use of such a formulation.
  • Mouth and nose represent the ways in which various conditions, from common flu to H1N1, and even bacterial and fungal infections settle in the human body.
  • An emblematic case allowing contamination of the mucous membranes of the nose and mouth is one that occurs where there is crowding of people, particularly indoors. Prevention of infections or contamination of any kind is sought by large numbers of people using cloth masks. Typical examples would be air travel, or hospital areas that visitors have to travel through.
  • Such masks generate discomfort in use, as well as disrupt the aesthetics, producing after use a material that requires treatment or burning before disposal.
  • Silver is one of the safest antimicrobial agents compared to some organic antimicrobial agents, with important antimicrobial effect and low toxicity to human cells.
  • silver particles of the formulation of the invention have typical sizes between 0.5 and 500 nm, particularly between 2 and 100 nm, more particularly between 10 and 50 nm.
  • silver is used in the formulation of the invention in the form of colloidal silver.
  • nanoprost such particles are termed nanoprost, without imposing any limitations beyond those contained in the appended claims.
  • the formulation of the invention during use favors the formation of silver ions.
  • the silver content in the formulation of the invention is in the range of 0.1 ppm to 2000 ppm per gram.
  • the formulation of the invention is in any form known to the person skilled in the art, suitable for contact with human mucous membranes, for example cream, gel, liquid, ointment, emulsion, dispersion, mouthwash, spray, foam, aerosol.
  • the formulation of the invention contains agents of mucosal adhesion, that is, a substrate compatible with mucosal contact, which has some degree of adherence to it, helping to fix the nanoprote in the vicinity of the mucosa.
  • Mucosal adhesion agents suitable for the invention may be aqueous or non-aqueous polymeric or non-polymeric substrates, for example chosen from polyethylene glycol, cellulose derivatives (methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, croscarmellose, etc.) polyvinyl pyrrolidone, pectin, hyaluronic acid , chitosan, polyvinyl alcohol, sodium alginate, polyorganosiloxane, polysaccharides, gelatin, gum tragacanth, xanthan gum, caraya gum, polyacrylic acid, soluble starch.
  • adhesion agents sometimes called bioadhesive or mucoadhesive, may be of plant or animal origin, or synthetic. May provide immediate, prolonged or delayed release of nanoprost.
  • the formulation of the invention may contain excipients adapted for use, for example rheological modifier, pH modifier, wetting, coloring, flavoring, surfactant, diluent, preservative, and any other known to the person skilled in the art.
  • the formulation of the invention may contain other topically desired actives such as other antimicrobials (antibacterial, antifungal, antiviral), anti-inflammatory, analgesic, anesthetic, hormone, etc.
  • other topically desired actives such as other antimicrobials (antibacterial, antifungal, antiviral), anti-inflammatory, analgesic, anesthetic, hormone, etc.
  • Another aspect of the invention is the use of formulation with the characteristics described above to prepare a product useful in preventing or treating mucosal disorders, particularly oral, nasal and vaginal mucosa.
  • the formulation of the invention may be indirectly dispensed to the mucosa, which is first applied to a suitable substrate such as cloth or cotton and then applied to the mucosa.
  • the following table shows a formulation according to the invention in the form of a topical antibacterial cream.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation mucosale antimicrobienne adhérant aux muqueuses, comprenant des particules d'argent, notamment des microparticules ou des nanoparticules d'argent, en vue de la prévention ou du traitement d'affections au niveau des muqueuses. L'invention concerne également l'ultilisation de cette formulation.
PCT/BR2017/050189 2016-07-14 2017-07-14 Formulation mucosale antimicrobienne et utilisation d'une formulation mucosale antimicrobienne Ceased WO2018009998A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRBR1020160163404 2016-07-14
BR102016016340-4A BR102016016340A2 (pt) 2016-07-14 2016-07-14 Formulação mucosal antimicrobiana e uso de formulação mucosal antimicrobiana

Publications (1)

Publication Number Publication Date
WO2018009998A1 true WO2018009998A1 (fr) 2018-01-18

Family

ID=60952269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2017/050189 Ceased WO2018009998A1 (fr) 2016-07-14 2017-07-14 Formulation mucosale antimicrobienne et utilisation d'une formulation mucosale antimicrobienne

Country Status (2)

Country Link
BR (1) BR102016016340A2 (fr)
WO (1) WO2018009998A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112759342A (zh) * 2020-12-31 2021-05-07 厦门高辰新材料有限公司 一种轻质抹灰石膏及其施工方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085385A2 (fr) * 2001-04-23 2002-10-31 Nucryst Pharmaceuticals Corp. Traitement de membranes muqueuses
US20030185889A1 (en) * 2002-03-27 2003-10-02 Jixiong Yan Colloidal nanosilver solution and method for making the same
US20070081958A1 (en) * 2003-08-29 2007-04-12 Thorsten Bechert Body care product containing porous silver particles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085385A2 (fr) * 2001-04-23 2002-10-31 Nucryst Pharmaceuticals Corp. Traitement de membranes muqueuses
US20030185889A1 (en) * 2002-03-27 2003-10-02 Jixiong Yan Colloidal nanosilver solution and method for making the same
US20070081958A1 (en) * 2003-08-29 2007-04-12 Thorsten Bechert Body care product containing porous silver particles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUMBERTO H LARA ET AL.: "Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds", JOURNAL OF NANOBIOTECHNOLOGY, vol. 9, 2011, pages 30, XP021105520 *
JUYOUNG KIM ET AL.: "Antimicrobial effect of silver-impregnated cellulose: potential for antimicrobial therapy", JOURNAL OF BIOLOGICAL ENGINEERING, vol. 3, 2009, pages 20, XP021070021 *

Also Published As

Publication number Publication date
BR102016016340A2 (pt) 2018-02-06

Similar Documents

Publication Publication Date Title
US6899897B2 (en) Gum resin as a carrier for topical application of pharmacologically active agents
US8709439B2 (en) Film-forming resins as a carrier for topical application of pharmacologically active agents
JP2007153910A (ja) 抗真菌マニキュア組成物
ES2834985T3 (es) Composición que contiene cineol para administración nasal
AU2002322011A1 (en) Gum resin as a carrier for topical application of pharmacologically active agents
CN102427811A (zh) 适于局部治疗皮肤和指(趾)甲真菌感染的组合物
CN111629711A (zh) 用于局部治疗皮肤感染和粘膜感染的乳剂
WO2018009998A1 (fr) Formulation mucosale antimicrobienne et utilisation d'une formulation mucosale antimicrobienne
US20140079814A1 (en) Method and Composition for Treating Gastro-Esophageal Disorders
JP2002114711A (ja) 外用剤組成物
HK1198632A1 (en) Compositions comprising cimetidine and n,o-carboxymethyl chitosan for the prevention and therapy of pathologies of the skin and the mucous membranes and in the odontostomatological field
ITMI20090829A1 (it) Composizioni oftalmiche per la riepitelizzazione, la cicatrizzazione, e la disinfezione dei tessuti oculari
CN1232305C (zh) 防腐剂
US9744125B2 (en) Use of a virucidal preparation on an area of the face for prevention of transmission or contraction of viral illnesses, or to shorten the duration of, or lessen the severity of viral illnesses
US20170326123A1 (en) Throat solution for treatment of cold, flu and sore throat
JP2011105764A (ja) 外用剤組成物
RU2021139253A (ru) Предотвращение заражения высокопатогенными вирусами путем местного нанесения повидон-йода на слизистые оболочки
AU2011244985B2 (en) Gum resin as a carrier for topical application of pharmacologically active agents
WO2022217319A1 (fr) Composition pour prophylaxie contre des pathogènes et procédés d'utilisation
IT202100022865A1 (it) Composizioni ad azione antivirale per somministrazione nasale od orofaringea a spruzzo
BR102022006318A2 (pt) Preparação medicinal à base de óleos essenciais para tratamento, prevenção e controle de mastite em animais
WO2017005398A1 (fr) Composition pour le traitement de la rhinite
CN108030782A (zh) 薁黄酸钠和西吡氯铵复方啫喱的制备及其应用
HK1169800A (en) Gum resin as a carrier for topical application of pharmacologically active agents
CA2746717A1 (fr) Creme antifongique contre l'erytheme fessier

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17826706

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 09-05-2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17826706

Country of ref document: EP

Kind code of ref document: A1